Item 6. EXHIBITS
9K characters. Original on sec.gov ·
Item 6. EXHIBITS
Exhibits (listed by number corresponding to the Exhibit Table of Item 601 in Regulation S-K).
| Exhibit No. | Description | |||||||
| 22. | Subsidiary Issuers of Guaranteed Securities (incorporated by reference to Exhibit 22 of Bristol Myers Squibb Company's Annual Report on Form 10-K filed on February 11, 2026) | |||||||
| 31a. | Section 302 Certification Letter (filed herewith). | |||||||
| 31b. | Section 302 Certification Letter (filed herewith). | |||||||
| 32a. | Section 906 Certification Letter (furnished herewith). | |||||||
| 32b. | Section 906 Certification Letter (furnished herewith). | |||||||
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |||||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | |||||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |||||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |||||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | |||||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
- Indicates, in this Quarterly Report on Form 10-Q, brand names of products, which are registered trademarks not solely owned by the Company or its subsidiaries. Keytruda and Winrevair are trademarks of Merck; Plavix is a trademark of Sanofi; and Tecentriq is a trademark of Genentech, Inc. Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of BMS and/or one of its subsidiaries.
SUMMARY OF ABBREVIATED TERMS
Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:
| 2025 Form 10-K | Annual Report on Form 10-K for the fiscal year ended December 31, 2025 | MCL | mantle cell lymphoma | ||||||||
| 2seventy bio | 2seventy bio, Inc. | Merck | Merck & Co., Inc., Rahway, NJ, USA | ||||||||
| ANDA | Abbreviated New Drug Application | MF | myelofibrosis | ||||||||
| AOCL | Accumulated other comprehensive loss | Mirati | Mirati Therapeutics, Inc. | ||||||||
| AstraZeneca | AstraZeneca PLC | MM | multiple myeloma | ||||||||
| AVD | doxorubicin, vinblastine and dacarbazine | MZL | marginal zone lymphoma | ||||||||
| BioArctic | BioArctic AB | NDA | New Drug Application | ||||||||
| BioNTech | BioNTech SE | NSCLC | non-small cell lung cancer | ||||||||
| Celgene | Celgene Corporation | NYHA | New York Heart Association | ||||||||
| CELMoD | cereblon E3 ligase modulator | oHCM | Obstructive Hypertrophic Cardiomyopathy | ||||||||
| CERCLA | U.S. Comprehensive Environmental Response, Compensation and Liability Act | Ono | Ono Pharmaceutical Co., Ltd | ||||||||
| cHL | classical Hodgkins Lymphoma | PD-1 | programmed cell death protein 1 | ||||||||
| CRC | colorectal cancer | PD-L1 | programmed death-ligand 1 | ||||||||
| CVR | Contingent value right | PDUFA | Prescription Drug User Fee Act | ||||||||
| Dr. Reddy's Laboratories | Dr. Reddy's Laboratories, Limited and Dr. Reddy's Laboratories, Inc. | Philochem | Philochem AG | ||||||||
| DVd | daratumumab, bortezomib and dexamethasone | Pfizer | Pfizer, Inc. | ||||||||
| EC | European Commission | PFS | progression-free survival | ||||||||
| EPS | earnings per share | PsA | psoriatic arthritis | ||||||||
| ESCC | esophageal squamous cell carcinoma | Quarterly Report on Form 10-Q | Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 | ||||||||
| ES-SCLC | extensive stage small cell lung cancer | R&D | research and development | ||||||||
| EU | European Union | RDFV | readily determinable fair values | ||||||||
| Evotec | Evotec SE | REMS | risk evaluation and mitigation strategy | ||||||||
| Exchange Act | the Securities Exchange Act of 1934 | Roche | F. Hoffman-La Roche & Co. | ||||||||
| FASB | Financial Accounting Standards Board | RRMM | relapsed or refractory multiple myeloma | ||||||||
| FDA | U.S. Food and Drug Administration | Sanofi | Sanofi S.A. | ||||||||
| GAAP | generally accepted accounting principles | SAR | Special Administrative Region | ||||||||
| GEP-NETs | gastroenteropancreatic neuroendocrine tumors | SEC | U.S. Securities and Exchange Commission | ||||||||
| GTN | gross-to-net | SPC | Supplementary Protection Certificate | ||||||||
| HCM | hypertrophic cardiomyopathy | SSTR+ | somatostatin receptor-positive | ||||||||
| Hengrui | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | SystImmune | SystImmune, Inc. | ||||||||
| HHS | Health and Human Services | TNBC | triple negative breast cancer | ||||||||
| IPF | idiopathic pulmonary fibrosis | UK | United Kingdom | ||||||||
| IPRD | in-process research and development | U.S. | United States | ||||||||
| IRA | Inflation Reduction Act of 2022 | VAT | value added tax | ||||||||
| IRS | Internal Revenue Service | VEGF-A | Vascular endothelial growth factor A | ||||||||
| IT | Information Technology | ||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| BRISTOL-MYERS SQUIBB COMPANY (REGISTRANT) | |||||||||||
| Date: | October 29, 2026 | By: | /s/ Christopher Boerner, Ph.D. | ||||||||
| Christopher Boerner, Ph.D. Chair of the Board and Chief Executive Officer | |||||||||||
| Date: | October 29, 2026 | By: | /s/ David V. Elkins | ||||||||
| David V. Elkins Chief Financial Officer |